Experimental and Clinical Results of Perioperative Treatment with Recombinant Human Erythropoietin
The side effects of allogeneic blood transfusions are nowadays well known . Especially the risk of transmitting viral infections is a reason to seek methods to reduce the need for allogeneic blood transfusions. Many retrospective studies suggest that in patients undergoing resection for malignancy there is a further adverse effect of blood transfusions: perioperative transfusions may stimulate tumor growth and therefore worsen the prognosis of these patients [2, 3]. Additionally, the rate of postoperative infectious complications may be increased if blood transfusions are given . All these effects can be avoided if the patient’s own blood is used because this is the safest blood to be transfused. Autologous transfusions can be achieved in several ways: (a) by predeposit autologous blood donations, (b) by preoperative intentional hemodilution, and (c) by reinfusion of blood saved during the operation. In cancer surgery these methods may have their limitations due to logistical problems and anemia. In addition, intraoperative cell saving is not allowed in cancer surgery because of the possibility of introducing metastases.
KeywordsPlacebo Corticosteroid Respiration Anemia Folate
Unable to display preview. Download preview PDF.
- 6.Hoynck van Papendrecht MAW, Jeekel J, Marquet RL. Dosage of recombinant human erythropoietin in autologous blood donation programs; a study in rats (submitted)Google Scholar
- 9.Levine EA, Gould SA, Rosen AL et al. (1989) Perioperative recombinant human erythropoietin. Surgery 106: 423–428Google Scholar
- 12.Hoynck van Papendrecht MAW, Jeekel J, Busch ORC, Marquet RL. The efficacy of recombinant erythropoietin to obviate the need for blood transfusions in surgery (in preparation)Google Scholar